瑞德西韦是否应用于治疗 COVID-19 患者？美国医师学会的快速实践要点（第 1 版）。
Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 1).
机构信息
American College of Physicians, Philadelphia, Pennsylvania (A.Q., I.E.).
American College of Physicians, Philadelphia, and Villanova University, Villanova, Pennsylvania (J.Y.).
出版信息
Ann Intern Med. 2021 Feb;174(2):229-236. doi: 10.7326/M20-5831. Epub 2020 Oct 5.
Abstract
These rapid and living practice points from the American College of Physicians address the effectiveness and harms of remdesivir treatment in patients with COVID-19.
摘要
美国医师学院的这些快速且实用的实践要点，探讨了瑞德西韦治疗 COVID-19 患者的有效性和危害。
相似文献
1
Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 1).瑞德西韦是否应用于治疗 COVID-19 患者？美国医师学会的快速实践要点（第 1 版）。
Ann Intern Med. 2021 Feb;174(2):229-236. doi: 10.7326/M20-5831. Epub 2020 Oct 5.
2
Update Alert 2: Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2).最新警报2：瑞德西韦是否应用于治疗新型冠状病毒肺炎患者？美国医师协会的快速实用要点（第2版）
Ann Intern Med. 2021 Dec;174(12):W116-W117. doi: 10.7326/L21-0607. Epub 2021 Oct 5.
3
Remdesivir for Adults With COVID-19 : A Living Systematic Review for American College of Physicians Practice Points.瑞德西韦治疗成人 COVID-19：美国医师学会实践要点的实时系统综述。
Ann Intern Med. 2021 Feb;174(2):209-220. doi: 10.7326/M20-5752. Epub 2020 Oct 5.
4
Remdesivir as a broad-spectrum antiviral drug against COVID-19.瑞德西韦作为一种广谱抗 COVID-19 病毒药物。
Eur Rev Med Pharmacol Sci. 2021 Jan;25(1):541-548. doi: 10.26355/eurrev_202101_24426.
5
Remdesivir (Veklury) for the Treatment of COVID-19 in Hospitalized Patients.瑞德西韦（Veklury）用于治疗住院的 COVID-19 患者。
Am Fam Physician. 2021 Sep 1;104(3):311-312.
6
Update Alert 2: Remdesivir for Adults With COVID-19.最新警报2：用于成人新冠肺炎患者的瑞德西韦。
Ann Intern Med. 2021 Dec;174(12):W114-W115. doi: 10.7326/L21-0600. Epub 2021 Oct 5.
7
Remdesivir (Veklury) for COVID-19.用于治疗新冠肺炎的瑞德西韦（Veklury）
Med Lett Drugs Ther. 2020 Nov 30;62(1612):186-188.
8
Audio Interview: New Data on Remdesivir in Covid-19.音频访谈：瑞德西韦治疗新冠病毒病的新数据
N Engl J Med. 2020 May 28;382(22):e94. doi: 10.1056/NEJMe2019975.
9
Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2).瑞德西韦是否应该用于治疗 COVID-19 患者？美国医师学会的快速、实用实践要点（第 2 版）。
Ann Intern Med. 2021 May;174(5):673-679. doi: 10.7326/M20-8101. Epub 2021 Feb 9.
10
Remdesivir for patients with COVID-19.瑞德西韦用于治疗新冠肺炎患者。
CMAJ. 2021 Jan 25;193(4):E125. doi: 10.1503/cmaj.202505. Epub 2021 Jan 6.
引用本文的文献
1
Potent Molecular Feature-based Neutralizing Monoclonal Antibodies as Promising Therapeutics Against SARS-CoV-2 Infection.基于强效分子特征的中和单克隆抗体有望成为抗SARS-CoV-2感染的治疗药物。
Front Mol Biosci. 2021 May 31;8:670815. doi: 10.3389/fmolb.2021.670815. eCollection 2021.
本文引用的文献
1
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.瑞德西韦对比标准治疗对 11 天内中症 COVID-19 患者临床状态的影响：一项随机临床试验。
JAMA. 2020 Sep 15;324(11):1048-1057. doi: 10.1001/jama.2020.16349.
2
Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.瑞德西韦治疗新冠病毒病-初步报告。回复。
N Engl J Med. 2020 Sep 3;383(10):994. doi: 10.1056/NEJMc2022236. Epub 2020 Jul 10.
3
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.瑞德西韦治疗重症 COVID-19 患者的 5 天与 10 天疗程比较
N Engl J Med. 2020 Nov 5;383(19):1827-1837. doi: 10.1056/NEJMoa2015301. Epub 2020 May 27.
4
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.瑞德西韦治疗成人重症 COVID-19 的随机、双盲、安慰剂对照、多中心临床试验。
Lancet. 2020 May 16;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9. Epub 2020 Apr 29.
5
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.预防性和治疗性瑞德西韦（GS-5734）治疗中东呼吸综合征冠状病毒感染恒河猴模型。
Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6771-6776. doi: 10.1073/pnas.1922083117. Epub 2020 Feb 13.
6
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.瑞德西韦和氯喹在体外能有效抑制新出现的新型冠状病毒（2019 - 新冠病毒）。
Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.
7
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV.比较瑞德西韦与洛匹那韦利托那韦和干扰素β联合治疗中东呼吸综合征冠状病毒的疗效。
Nat Commun. 2020 Jan 10;11(1):222. doi: 10.1038/s41467-019-13940-6.
8
Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase.广谱抗病毒药物瑞德西韦通过高度分化的 RNA 依赖的 RNA 聚合酶抑制人类地方性和人畜共患的德尔塔冠状病毒。
Antiviral Res. 2019 Sep;169:104541. doi: 10.1016/j.antiviral.2019.104541. Epub 2019 Jun 21.
9
Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies.埃博拉病毒在非人灵长类动物中的动态变化为研究病毒的免疫发病机制和抗病毒策略提供了线索。
Nat Commun. 2018 Oct 1;9(1):4013. doi: 10.1038/s41467-018-06215-z.
10
Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease.冠状病毒对抗病毒药物瑞德西韦（GS-5734）的易感性是由病毒聚合酶和校对核糖核酸外切酶介导的。
mBio. 2018 Mar 6;9(2):e00221-18. doi: 10.1128/mBio.00221-18.
Zotero 插件